Moletest Seeks Partners For Melanoma Screening Technology
Moletest has developed an iPad-based system for screening skin lesions suspected of melanoma.
You may also be interested in...
The Dutch company received the US FDA's breakthrough device designation in 2018 for the surgical patch.
Johnson & Johnson previously agreed to acquire TachoSil but terminated the transaction due to regulatory hurdles.
Emmanuel Ligner, president and CEO of Cytiva, talks to In Vivo about how the company will dramatically increase its manufacturing capabilities over the next five years, at a price tag of $500m.